Design Therapeutics (DSGN) Profit After Tax (2020 - 2026)

Design Therapeutics has reported Profit After Tax for 7 years, with the latest figure at -$20.2 million in Q2 2026.

• Profit After Tax for Q2 2026 came in at -$20.2 million, down 5.67% year-over-year; the trailing twelve-month figure through Jun 2026 was -$70.8 million (down 11.51% YoY), and the FY2025 annual result was -$69.8 million, down 40.74% from the prior year.
• Profit After Tax fell to -$20.2 million in Q2 2026, from -$17.6 million in the prior quarter.
• Over five years, Profit After Tax peaked at -$11.3 million in Q1 2024 and troughed at -$20.2 million in Q2 2026.
• A 5-year average of -$16.2 million and a median of -$16.4 million in 2022 frame the typical range for Profit After Tax.
• The widest annual swing landed in 2022, when Profit After Tax sank 153.05%; it then surged 41.26% in 2024.
• A 5-year view of Profit After Tax shows it stood at -$16.8 million in 2022, then increased by 29.66% to -$11.8 million in 2023, then declined by 15.28% to -$13.7 million in 2024, then retreated by 17.19% to -$16.0 million in 2025, then declined by 26.05% to -$20.2 million in 2026.
• Per Business Quant data, the three most recent Profit After Tax figures were -$20.2 million in Q2 2026, -$17.6 million in Q1 2026, and -$16.0 million in Q4 2025.